Mixed‐Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • ABSTRACTThe prevalence of mixed hepatitis C virus (HCV) genotype infection in a representative Canadian HCV cohort is reported and virological response with direct acting antiviral (DAA) treatment was evaluated. 3272 HCV‐positive participants were enrolled, of which 2945 (90.0%) initiated DAA therapy. 0.8% were identified with mixed genotype infection. Overall sustained virological response (SVR) was 99.1% and did not differ based on mixed genotype status. Any historical disadvantage to achieving cure with HCV treatment in mixed genotype infection has been overcome by current DAA regimens.

authors

  • Imsirovic, Haris
  • Macphail, Gisela
  • Conway, Brian
  • Fraser, Chris
  • Borgia, Sergio
  • Smyth, Daniel
  • Wong, Alexander
  • Vachon, Marie‐Louise
  • Webster, Duncan
  • Liu, Hongqun
  • Feld, Jordan
  • Lee, Sam
  • Cooper, Curtis

publication date

  • November 2024